ArticleAesthetic plastic surgery2026
Polynucleotide (PN) Therapy for Accelerated Wound Repair and Scar Modulation in Aesthetic Procedures.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative wound compromise after aesthetic procedures may manifest as delayed epithelialization, tissue ischemia, hypertrophic scarring, contour depression, or wound dehiscence. These problems are more common in patients with impaired microcirculation or other healing-related comorbidities.
objectivesTo describe the clinical use of injectable polynucleotide as an adjunctive treatment for postoperative wound healing and scar modulation after aesthetic procedures.
methodsThis retrospective case series included eight consecutive patients treated in routine practice at a single aesthetic clinic over a continuous study accrual period. Eligible patients had clinically significant wound healing delay, early ischemic change, hypertrophic scarring, or postoperative contour depression after aesthetic surgery or facial trauma and were managed with injectable polynucleotide (Rejuran). Treatments were individualized according to wound status and tissue quality, typically using 1-2 mL per session at 2- to 3-week intervals. Because of the heterogeneous case mix and retrospective design, outcomes were evaluated by serial standardized clinical photographs and physician-rated changes in wound size, erythema, scar width/elevation, and contour rather than by a single validated scar scale.
resultsAll eight patients demonstrated clinical improvement after treatment, including faster re-epithelialization, reduction of erythema, narrowing and flattening of scars, improved contour, or complete wound closure. Earlier treatment during the inflammatory or early proliferative phase appeared to produce the most favorable results. No treatment-related adverse events were documented.
conclusionsThe application of injectable polynucleotide therapy appears to be a safe and useful adjunct for postoperative wound care and scar modulation in aesthetic practice. Early use may be especially helpful in patients at high risk for wound breakdown, although prospective studies using standardized outcome measures are needed. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.